Article Figures & Data
Figures
- FIGURE 1.
(A) Schematic structure of 68Ga-BBN. (B) Representative maximum-intensity-projection torso images of healthy volunteer at different time points after intravenous injection of 68Ga-BBN. Main regions with prominent 68Ga-BBN uptake are pancreas, kidneys, urinary ducts, and bladder.
- FIGURE 2.
Representative 68Ga-BBN PET/CT images (left), MR images (middle), and immunohistochemically stained tissue samples (right) of patients with gliomas of different grades. (A) A 5-y-old girl with space-occupying lesion in cerebellar lobe diagnosed as pilocytic astrocytoma, WHO grade I. Lesion had SUVmax of 2.35 and SUVmean of 1.31, showed enhancement on T1-weighted MRI, and stained positively for GRPR. (B) A 4-y-old girl with multiple space-occupying lesions diagnosed as WHO grade II astrocytoma. Lesions had SUVmax of 2.05 and SUVmean of 1.45, were identified by contrast-enhanced T1-weighted MRI, and stained positively for GRPR. (C) A 14-y-old boy with space-occupying lesion in thalamic connections of temporal lobe diagnosed as WHO grade III anaplastic oligoastrocytoma. Lesion had SUVmax of 1.98 and SUVmean of 1.08, showed enhancement on T1-weighted MRI, and stained positively for GRPR. (D) A 44-y-old man with space-occupying lesion in left temporal lobe diagnosed as WHO grade IV glioblastoma multiforme. Lesion had SUVmax of 1.95 and SUVmean of 0.98, showed enhancement on T2-weighted MRI, and stained positively for GRPR.
- FIGURE 3.
Correlation of SUVmax (A) and SUVmean (B) as determined by 68Ga-BBN PET with GRPR expression level as determined by immunohistochemical staining (r2 = 0.71, P < 0.001, for SUVmax and r2 = 0.54, P < 0.01, for SUVmean).
Tables
Patient no. Age (y) Sex WHO grade Histology Location MRI findings 1 12 M I Ganglioglioma Third ventricle Heterogeneous, intense 2 39 M III Anaplastic oligoastrocytoma Right frontal Heterogeneous, intense 3 14 M III Anaplastic oligoastrocytoma Thalamus, temporal lobe Heterogeneous, intense 4 4 F II Astrocytoma Seller area Heterogeneous, intense 5 5 M II Pilocytic astrocytoma with necrosis Seller area Heterogeneous, moderate 6 5 F I Pilocytic astrocytoma Cerebellar lobe Heterogeneous, moderate 7 33 F I Pilocytic astrocytoma Seller area Heterogeneous, intense 8 34 M III Anaplastic oligoastrocytoma Frontal lobe Heterogeneous, moderate 9 37 M IV Glioblastoma multiforme Frontal lobe Heterogeneous, intense 10 34 F II Oligoastrocytoma Left frontal Not applicable 11 12 M I Pilocytic astrocytoma Seller area Homogeneous, intense 12 44 M IV Glioblastoma multiforme Left temporal lobe Homogeneous, intense Time (min) Organ 1 5 10 15 30 45 60 Brain 0.23 ± 0.05 0.18 ± 0.05 0.18 ± 0.05 0.15 ± 0.06 0.15 ± 0.06 0.13 ± 0.05 0.15 ± 0.06 Heart 3.50 ± 0.59 2.88 ± 0.43 2.30 ± 0.23 1.85 ± 0.21 1.60 ± 0.18 1.43 ± 0.22 1.25 ± 0.24 Lung 1.13 ± 0.26 0.81 ± 0.06 0.70 ± 0.08 0.60 ± 0.18 0.50 ± 0.08 0.40 ± 0.08 0.43 ± 0.10 Liver 2.68 ± 0.32 2.18 ± 0.78 1.58 ± 0.21 1.55 ± 0.37 1.43 ± 0.26 1.33 ± 0.26 1.25 ± 0.17 Spleen 2.84 ± 0.30 2.18 ± 0.74 1.65 ± 0.38 1.53 ± 0.43 1.58 ± 0.36 1.50 ± 0.35 1.30 ± 0.35 Pancreas 13.59 ± 2.29 19.79 ± 2.32 20.05 ± 2.11 20.06 ± 4.19 17.15 ± 3.00 13.10 ± 0.14 12.70 ± 2.00 Kidneys 7.73 ± 1.03 6.83 ± 1.26 7.88 ± 3.59 4.88 ± 0.62 3.83 ± 0.63 3.15 ± 0.77 2.70 ± 0.54 Bladder 2.58 ± 1.44 42.67 ± 5.57 74.86 ± 5.51 80.57 ± 5.71 80.30 ± 6.55 75.95 ± 7.23 71.63 ± 5.96 Red marrow 0.50 ± 0.45 0.80 ± 0.24 0.90 ± 0.29 0.85 ± 0.24 0.78 ± 0.24 0.80 ± 0.41 0.73 ± 0.26 Muscle 0.18 ± 0.05 0.48 ± 0.05 0.53 ± 0.10 0.53 ± 0.10 0.45 ± 0.06 0.45 ± 0.06 0.40 ± 0.08 Data are mean SUV ± SD (n = 4).
mSv/MBq Organ Mean SD Adrenals 0.00021 0.00004 Brain 0.00001 0.00001 Breasts 0.00004 0.00002 Gallbladder wall 0.00053 0.00013 Lower large intestine wall 0.00566 0.00121 Small intestine 0.00228 0.00057 Stomach wall 0.00032 0.00001 Upper large intestine wall 0.00174 0.00044 Heart wall 0.00017 0.00001 Kidneys 0.00058 0.00013 Liver 0.00032 0.00006 Lungs 0.00009 0.00003 Muscle 0.00139 0.00025 Ovaries 0.00530 0.00124 Pancreas 0.00105 0.00015 Red marrow 0.00098 0.00022 Osteogenic cells 0.00058 0.00011 Skin 0.00050 0.00001 Spleen 0.00032 0.00007 Testes 0.01000 — Thymus 0.00159 0.00177 Thyroid 0.00004 0.00001 Urinary bladder wall 0.30700 0.35559 Uterus 0.01310 — Total body 0.00150 0.00029 Effective dose equivalent 0.03350 0.00790 Effective dose 0.02760 0.00660
Jump to section
Related Articles
Cited By...
- Head-to-Head Comparison of [68Ga]Ga-NOTA-RM26 and [18F]FDG PET/CT in Patients with Gastrointestinal Stromal Tumors: A Prospective Study
- PET Using a GRPR Antagonist 68Ga-RM26 in Healthy Volunteers and Prostate Cancer Patients
- Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers
- Clinical Translation of a Dual Integrin {alpha}v{beta}3- and Gastrin-Releasing Peptide Receptor-Targeting PET Radiotracer, 68Ga-BBN-RGD